Lamotrigine in the maintenance treatment of bipolar disorder

Lamotrigine, an anticonvulsant drug, is licensed in the United States for the maintenance treatment of bipolar I disorder and in the UK to prevent depressive episodes in bipolar disorder. Hashimoto and colleagues (2021) performed a Cochrane Intervention Review to explore whether lamotrigine is effective and safe compared to the most established maintenance treatment, lithium, and placebo.

Michael Ostacher critically appraises and summarises a recent Cochrane systematic review, which presents the latest best evidence on the efficacy of lamotrigine in the maintenance treatment of bipolar disorder.

[read the full story...]

Pregnancy and bipolar disorder: international prescribing consensus?

Pregnant woman with drugs

Dean Connolly looks at an international study which asks: Is there consensus across evidence-based guidelines for the psychotropic drug management of bipolar disorder during the perinatal period?

[read the full story...]

Lamotrigine for “Borderline Personality Disorder”: should we prescribe it? #BIGSPD19

charisse-kenion-1417690-unsplash

Keir Harding prepares for the #BIGSPD19 conference by reading Mike Crawford et al’s recent RCT on the clinical effectiveness and cost-effectiveness of lamotrigine in borderline personality disorder.

[read the full story...]

Lamotrigine, quetiapine and folic acid for bipolar depression: the CEQUEL trial

15802794635_256de371d5_k

Michael Ostacher considers the findings of the CEQUEL trial, which asks: Does lamotrigine treat bipolar depression when added to quetiapine, and does adding folic acid help any more?

[read the full story...]